Literature DB >> 22751696

Dysregulated Toll-like receptor-induced interleukin-1β and interleukin-6 responses in subjects at risk for the development of type 1 diabetes.

Aimon K Alkanani1, Marian Rewers, Fran Dong, Kathleen Waugh, Peter A Gottlieb, Danny Zipris.   

Abstract

We tested the hypothesis that altered Toll-like receptor (TLR) signaling may be involved in early stages of type 1 diabetes (T1D). To do so, we analyzed TLR-induced interleukin (IL)-1β and IL-6 responses in freshly isolated peripheral blood mononuclear cells (PBMNCs) from seropositive compared with seronegative subjects. Similar frequencies of myeloid dendritic cells (mDCs), plasmacytoid DCs (pDCs), and monocytes were observed in seropositive and seronegative subjects. Subjects with autoantibodies had increased proportions of monocytes expressing IL-1β ex vivo. Activating PBMNCs with TLR3, TLR4, or TLR7/8 agonists in vitro led to increased percentages of IL-1β-expressing monocytes and mDCs from seropositive versus seronegative subjects. TLR ligation also resulted in a diminished IL-6 response in seropositive individuals as lower frequencies of IL-6-expressing monocytes and mDCs were induced. The dysregulated TLR-induced IL-1β and IL-6 pathways were more readily detectable in children aged <11 years and from 11 to <21 years, respectively, and did not involve altered HbA(1c) or the presence of one or more autoantibodies. Finally, subjects with autoantibodies had lower amounts of serum chemokine (C-X-C motif) ligand 10 compared with autoantibody-negative subjects. Our data may imply that alterations in innate immune pathways are detectable in genetically susceptible individuals and could be linked with the early course of T1D.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22751696      PMCID: PMC3447890          DOI: 10.2337/db12-0099

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  35 in total

Review 1.  Innate immune recognition.

Authors:  Charles A Janeway; Ruslan Medzhitov
Journal:  Annu Rev Immunol       Date:  2001-10-04       Impact factor: 28.527

2.  Altered Toll-like receptor signaling pathways in human type 1 diabetes.

Authors:  Adam J Meyers; Roopali R Shah; Peter A Gottlieb; Danny Zipris
Journal:  J Mol Med (Berl)       Date:  2010-08-20       Impact factor: 4.599

3.  TLR activation synergizes with Kilham rat virus infection to induce diabetes in BBDR rats.

Authors:  Danny Zipris; Egil Lien; Jenny X Xie; Dale L Greiner; John P Mordes; Aldo A Rossini
Journal:  J Immunol       Date:  2005-01-01       Impact factor: 5.422

Review 4.  The role of interleukin-1 in the pathogenesis of IDDM.

Authors:  T Mandrup-Poulsen
Journal:  Diabetologia       Date:  1996-09       Impact factor: 10.122

5.  Mediators of inflammation in children with type I diabetes mellitus: cytokines in type I diabetic children.

Authors:  A B Erbağci; M Tarakçioğlu; Y Coşkun; E Sivasli; E Sibel Namiduru
Journal:  Clin Biochem       Date:  2001-11       Impact factor: 3.281

Review 6.  The stages of type 1A diabetes: 2005.

Authors:  Roberto Gianani; George S Eisenbarth
Journal:  Immunol Rev       Date:  2005-04       Impact factor: 12.988

7.  Serum levels of the interferon-gamma-inducing cytokine interleukin-18 are increased in individuals at high risk of developing type I diabetes.

Authors:  F Nicoletti; I Conget; R Di Marco; A M Speciale; R Morìnigo; K Bendtzen; R Gomis
Journal:  Diabetologia       Date:  2001-03       Impact factor: 10.122

Review 8.  A choice of death--the signal-transduction of immune-mediated beta-cell apoptosis.

Authors:  D L Eizirik; T Mandrup-Poulsen
Journal:  Diabetologia       Date:  2001-12       Impact factor: 10.122

9.  [Plasma levels of interleukin-1beta, interleukin-2 and interleukin-4 in recently diagnosed type 1 diabetic children and their association with beta-pancreatic autoantibodies].

Authors:  Francisco Pérez; Amaya Oyarzún; Elena Carrasco; Bárbara Angel; Cecilia Albala; J Luis Santos
Journal:  Rev Med Chil       Date:  2004-04       Impact factor: 0.553

10.  Clinical characteristics of children diagnosed with type 1 diabetes through intensive screening and follow-up.

Authors:  Jennifer M Barker; Stephanie H Goehrig; Katherine Barriga; Michelle Hoffman; Robert Slover; George S Eisenbarth; Jill M Norris; Georgeanna J Klingensmith; Marian Rewers
Journal:  Diabetes Care       Date:  2004-06       Impact factor: 19.112

View more
  25 in total

Review 1.  Type 1 diabetes therapy beyond T cell targeting: monocytes, B cells, and innate lymphocytes.

Authors:  F Susan Wong; Li Wen
Journal:  Rev Diabet Stud       Date:  2012-12-28

Review 2.  Targeting Innate Immunity for Type 1 Diabetes Prevention.

Authors:  James C Needell; Danny Zipris
Journal:  Curr Diab Rep       Date:  2017-09-27       Impact factor: 4.810

Review 3.  Redox stress unbalances the inflammatory cytokine network: role in autoinflammatory patients and healthy subjects.

Authors:  Rosa Lavieri; Anna Rubartelli; Sonia Carta
Journal:  J Leukoc Biol       Date:  2015-07-21       Impact factor: 4.962

4.  Alterations in Intestinal Microbiota Correlate With Susceptibility to Type 1 Diabetes.

Authors:  Aimon K Alkanani; Naoko Hara; Peter A Gottlieb; Diana Ir; Charles E Robertson; Brandie D Wagner; Daniel N Frank; Danny Zipris
Journal:  Diabetes       Date:  2015-06-11       Impact factor: 9.461

5.  Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials.

Authors:  Antoinette Moran; Brian Bundy; Dorothy J Becker; Linda A DiMeglio; Stephen E Gitelman; Robin Goland; Carla J Greenbaum; Kevan C Herold; Jennifer B Marks; Philip Raskin; Srinath Sanda; Desmond Schatz; Diane K Wherrett; Darrell M Wilson; Jeffrey P Krischer; Jay S Skyler; Linda Pickersgill; Eelco de Koning; Anette-G Ziegler; Bernhard Böehm; Klaus Badenhoop; Nanette Schloot; Jens Friis Bak; Paolo Pozzilli; Didac Mauricio; Marc Y Donath; Luis Castaño; Ana Wägner; Hans Henrik Lervang; Hans Perrild; Thomas Mandrup-Poulsen
Journal:  Lancet       Date:  2013-04-05       Impact factor: 79.321

Review 6.  Interleukin-1 antagonists and other cytokine blockade strategies for type 1 diabetes.

Authors:  Thomas Mandrup-Poulsen
Journal:  Rev Diabet Stud       Date:  2012-12-28

7.  MD-2 is involved in the stimulation of matrix metalloproteinase-1 expression by interferon-γ and high glucose in mononuclear cells - a potential role of MD-2 in Toll-like receptor 4-independent signalling.

Authors:  Zhongyang Lu; Yanchun Li; Devadoss J Samuvel; Junfei Jin; Xiaoming Zhang; Maria F Lopes-Virella; Yan Huang
Journal:  Immunology       Date:  2013-11       Impact factor: 7.397

Review 8.  Gut microbiota and type 1 diabetes.

Authors:  Outi Vaarala
Journal:  Rev Diabet Stud       Date:  2012-12-28

9.  α1-Antitrypsin therapy downregulates toll-like receptor-induced IL-1β responses in monocytes and myeloid dendritic cells and may improve islet function in recently diagnosed patients with type 1 diabetes.

Authors:  Peter A Gottlieb; Aimon K Alkanani; Aaron W Michels; Eli C Lewis; Leland Shapiro; Charles A Dinarello; Danny Zipris
Journal:  J Clin Endocrinol Metab       Date:  2014-02-14       Impact factor: 5.958

Review 10.  Islet inflammation: a unifying target for diabetes treatment?

Authors:  Yumi Imai; Anca D Dobrian; Margaret A Morris; Jerry L Nadler
Journal:  Trends Endocrinol Metab       Date:  2013-02-26       Impact factor: 12.015

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.